| abstract |
A compound of the formula (1), or a pharmaceutically acceptable salt or ester thereof for cancer treatment is provided, where (i) the cancer is a cancer that has the characteristic of being a type that tends to be or become refractory or resistant to a therapy based on the platinum drug and (ii) the treatment is carried out with a dose of between 1 mg / m² and 30 mg / m² of compound per surface area of the patient's body per administration. Methods of treatment dosage forms are also provided. Ovarian cancers, particularly those expressing a-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer, are particularly treated. |